Home Cart Sign in  
Chemical Structure| 368449-04-1 Chemical Structure| 368449-04-1

Structure of MST-312
CAS No.: 368449-04-1

Chemical Structure| 368449-04-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MST-312, also called Telomerase inhibitor IX, is a synthetic compound that acts as a reversible TERT (telomerase) inhibitor, and is described to be more potent than epigallocatechin gallate.

Synonyms: Telomerase Inhibitor IX

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MST-312

CAS No. :368449-04-1
Formula : C20H16N2O6
M.W : 380.35
SMILES Code : O=C(NC1=CC=CC(NC(C2=CC=CC(O)=C2O)=O)=C1)C3=CC=CC(O)=C3O
Synonyms :
Telomerase Inhibitor IX
MDL No. :MFCD24368986

Safety of MST-312

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H318-H400
Precautionary Statements:P280-P305+P351+P338+P310
Class:9
UN#:3077
Packing Group:

Related Pathways of MST-312

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 10 µM 24 hours Inhibited telomerase activity, reduced CD133 (+) subpopulation Int J Oncol. 2016 Aug;49(2):487-98
MDA-MB-231 10 µM 24 hours Reduced CD44 (+) subpopulation, inhibited wound healing capacity Int J Oncol. 2016 Aug;49(2):487-98
SW620 10 µM 24 hours Inhibited telomerase activity, reduced CD133 (+) subpopulation Int J Oncol. 2016 Aug;49(2):487-98
KNS60 cells 1.0 μM 48 hours Assessed the inhibitory effect of MST-312 on telomerase activity, showing inhibition. Mol Cancer. 2014 Oct 13;13:232
MO59K cells 1.0 μM 48 hours Assessed the inhibitory effect of MST-312 on telomerase activity, showing reversible inhibition. Mol Cancer. 2014 Oct 13;13:232
ONS76 cells 1.0 μM 48 hours Assessed the inhibitory effect of MST-312 on telomerase activity, showing dose-dependent inhibition. Mol Cancer. 2014 Oct 13;13:232
OSE (Human Ovarian Surface Epithelial cells) 0.01–50 µM 72 hours MST-312 had an IC50 of 8 µM in OSE cells and showed cytoprotective effects at low concentrations. Transl Oncol. 2023 Jan;27:101569
HCT116 (colorectal carcinoma) 0.01–50 µM 72 hours MST-312 induced cytotoxicity in a dose-dependent manner with IC50 of 5.9 µM. Transl Oncol. 2023 Jan;27:101569
A2780cisR (ovarian adenocarcinoma cisplatin-resistant cell line) 0.01–50 µM 72 hours MST-312 induced cytotoxicity in a dose-dependent manner with IC50 of 3.6 µM. Transl Oncol. 2023 Jan;27:101569
OVCAR3 (ovarian adenocarcinoma cell line) 0.01–50 µM 72 hours MST-312 induced cytotoxicity in a dose-dependent manner with IC50 of 7.1 µM. Transl Oncol. 2023 Jan;27:101569
A2780 (ovarian adenocarcinoma cell line) 0.01–50 µM 72 hours MST-312 induced cytotoxicity in a dose-dependent manner with IC50 of 3.9 µM. Transl Oncol. 2023 Jan;27:101569
PA-1 (ovarian teratocarcinoma cell line) 0.01–50 µM 72 hours MST-312 induced cytotoxicity in a dose-dependent manner with IC50 of 4.2 µM. Transl Oncol. 2023 Jan;27:101569
H1299 cells 0.25 μM 120 hours MST312 significantly inhibited H1299 cell proliferation, with ALDH+ cells being more sensitive than ALDH- cells. Mol Cancer. 2011 Aug 9;10:96
H460 cells 1 μM 120 hours MST312 exhibited a dose-dependent antiproliferative effect on H460 cells, with ALDH+ cells being more sensitive than ALDH- cells. Mol Cancer. 2011 Aug 9;10:96
MDA-MB-435 0.23 μM (IC50) 24 hours To investigate the inhibitory effect of MST-312 on telomerase activity and its impact on cancer cell survival. Results showed that MST-312 inhibited telomerase activity in a concentration-dependent manner with an IC50 of 0.23 μM. Eur J Med Chem. 2017 Jan 5;125:117-129
primary ependymoma cells 0 to 4 μM 72 hours To evaluate the effect of MST-312 on cell viability. Results showed a significant decrease in cell number (P<0.001), increased DNA damage (γH2AX expression, P<0.01), decreased proliferative index (MIB-1, P<0.01), and increased apoptosis in some cells (cleaved caspase 3). Brain Pathol. 2010 Jul;20(4):780-6
NCI-H441 cells 2.5 μM 28 days Induced cellular senescence and increased secretion of pro-inflammatory cytokines Respir Res. 2011 Jun 10;12(1):78
Leishmania major promastigote cells 0.1 to 4 µM 30 minutes To test the effect of human telomerase inhibitors on L. major telomerase activity. Both MST-312 and TMPyP4 effectively inhibited L. major telomerase activity, with MST-312 being more potent, achieving complete inhibition at 0.5µM, which is eight times lower than the concentration required for TMPyP4. Microorganisms. 2025 Feb 7;13(2):357
FLO-1 cells 1 μM 10 days To evaluate the antiproliferative effect of MST-312 analog GRN163L on H460 cells, results showed that SFN enhanced the activity of GRN163L. Transl Oncol. 2010 Dec 1;3(6):389-99
HEp-2 cells 20-100 μM 18 hours MST-312 inhibits HSV-1 replication, reduces viral protein accumulation. J Virol. 2015 Oct;89(19):9804-16
hTERT-HME1 cells 20-100 μM 18 hours MST-312 inhibits HSV-1 replication, reduces cytopathic effects and viral protein accumulation. J Virol. 2015 Oct;89(19):9804-16

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic mice H460 xenograft model Intraperitoneal injection 40 mg/kg Once daily for 25 days MST312 significantly reduced tumor volume (70% reduction), decreased the number of ALDH+ CSCs, and induced apoptosis. Mol Cancer. 2011 Aug 9;10:96

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.15mL

2.63mL

1.31mL

26.29mL

5.26mL

2.63mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories